Clinical TrialsAcquired asset, ocedurenone, fails in pre-specified interim analysis for Ph 3 CLARION-CKD trial.
Financial PerformanceAs a result of this failure, Novo will recognize a DKK 5.7B impairment charge and will look to reevaluate other current trials for indication expansion.
RevenueObesity care demand has continued to climb, revenue fell short of expectations with Wegovy missing estimates by 10%.